8 4 • O U T PA T I E N T S U R G E R Y M A G A Z I N E • A P R I L 2 0 2 0
O
phthalmology has a long history of innovation, and
we're fortunate to have access to several cutting-edge
treatments that reduce pain and inflammation after
cataract procedures, thereby reducing the need for
post-op eyedrop therapies.
• Omidria (1 % phenylephrine and .3 % ketorolac) is an irrigating
solution administered with balanced saline solution during surgery to
maintain pupil dilation and reduce post-op pain. It costs about $465 per
Don't Pass Up Pass-Through Payments
Understanding the billing process will ensure your
cataract patients have access to new and innovative medications.
Lisa M. Nijm, MD, JD | Warrenville, Ill.
• INNOVATIVE MEDS Ophthalmic drugs improve patient care, but their pass-through funding status can be cumbersome to
navigate.
